FStar.jpg
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
November 12, 2021 08:00 ET | F-star Therapeutics, Inc.
Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s...
Picture1.jpg
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
November 11, 2021 16:05 ET | Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Picture1.jpg
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
November 10, 2021 16:05 ET | Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 10, 2021 16:05 ET | Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
Featured Image for CytoImmune Therapeutics
CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer
November 10, 2021 08:00 ET | CytoImmune Therapeutics
LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a privately-held cell therapy company focused on developing natural killer (NK) immune cells to fight cancer, announces the...
PDS Biotech Logo.png
PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 07:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
Aprea logo 445pt.png
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
November 08, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
RevolutionLogo.png
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 08, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
LogoPressRelease.jpg
Fluidigm Announces Third Quarter 2021 Financial Results
November 08, 2021 16:02 ET | Fluidigm Corporation
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology...
PDS Biotech Logo.png
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
November 08, 2021 08:30 ET | PDS Biotechnology Corporation
Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...